SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen
- 1 February 2021
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (2), 892-898
- https://doi.org/10.1002/jmv.26320
Abstract
Since its emergence in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has developed into a global pandemic within a matter of months. While subunit vaccines are one of the prominent options for combating coronavirus disease 2019 (COVID-19), the immunogenicity of spike protein-based antigens remains unknown. When immunized in mice, the S1 domain induced much higher IgG and IgA antibody levels than the receptor-binding domain (RBD) and more efficiently neutralized SARS-CoV-2 when adjuvanted with alum. It is inferred that a large proportion of these neutralization epitopes are located in the S1 domain but outside the RBD and that some of these are spatial epitopes. This finding indicates that expression systems with posttranslational modification abilities are important to maintain the natural configurations of recombinant spike protein antigens and are critical for effective COVID-19 vaccines. Further, adjuvants prone to a Th1 response should be considered for S1-based subunit COVID-19 vaccines to reduce the potential risk of antibody-dependent enhancement of infection.This publication has 48 references indexed in Scilit:
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR PathwayJournal of Virology, 2011
- Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody ProductionJournal of Virology, 2011
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal modelVaccine, 2007
- Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine DesignJournal of Virology, 2006
- Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccineReviews in Medical Virology, 2006
- SARS Vaccine DevelopmentEmerging Infectious Diseases, 2005
- Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related toStreptococcus pneumoniaeType 3Infection and Immunity, 2003
- The profile of IgG1 and IgG2a antibody responses in mice exposed to Schistosoma mansoniParasite Immunology, 1994